NCT04084249Active, not recruiting
ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial
Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer - Intervention Trial 2
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
IMPROVE-IT2 is a randomized multicenter trial comparing the outcomes of ctDNA guided post-operative surveillance and standard-of-care CT-scan surveillance. The hypothesis of this study is that ctDNA guided post-operative surveillance combining ctDNA and radiological assessments could result in earlier detection of recurrent disease and identify more patients eligible for curative treatment.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 359 (actual)
- First submitted
- 4 Sept 2019
- Start date
- 1 Jan 2020
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- Claus Lindbjerg Andersen
- Diseases
- Colorectal cancer
- NCT number
- NCT04084249
What you commit to
- Study type: Interventional
- Participants enrolled: 359
- From 1 Jan 2020 to the primary completion date, 30 Jun 2028
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Not treated with adjuvant chemotherapy
Other illness
- Synchronous colorectal and non-colorectal cancer diagnosed per-operative (except skin cancer other than melanoma)
- Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from screening
Other
- Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study.
Who the study is looking for
- Colon or rectal cancer, tumor stage III (pT1-4N1-2,cM0) or stage II high-risk (pT4N0,cM0 and pT3N0, cM0 with risk factors)
- Have received curative intend resection and be candidates for adjuvant chemotherapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aalborg University Hospital Coordinator of this site? Confirm its status | Aalborg | Denmark | Unknown status |
| Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus | Denmark | Unknown status |
| Bispebjerg Hospital Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
| Herlev Hospital Coordinator of this site? Confirm its status | Herlev | Denmark | Unknown status |
| Gødstrup Hospital Coordinator of this site? Confirm its status | Herning | Denmark | Unknown status |
| Regional Hospital Horsens Coordinator of this site? Confirm its status | Horsens | Denmark | Unknown status |
| Zealand University Hospital Coordinator of this site? Confirm its status | Køge | Denmark | Unknown status |
| Odense University Hospital Coordinator of this site? Confirm its status | Odense | Denmark | Unknown status |
| Regional Hospital Randers Coordinator of this site? Confirm its status | Randers | Denmark | Unknown status |
| Regional Hospital Viborg Coordinator of this site? Confirm its status | Viborg | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.